Nevro Corp.’s stock was up following encouraging results detailed during its fourth-quarter earnings call. Management predicted a positive 2020, highlighting the potential of the U.S. spinal cord stimulation (SCS) market. Keith Grossman, chair, CEO and president of the company, noted that the SCS market slowed last year as a result of stocking issues – a challenge that affected both it and its competitors.
Keeping you up to date on recent developments in neurology, including: Therapeutic cooling targets site of newborn brain injury; Boys with inattention-hyperactivity face increased risk for traumatic brain injuries; Nanogold improves MS symptoms; Thanks for the memories, myelin.
Cambridge, Mass., startup Enclear Therapies Inc. has secured $10 million in series A financing led by 20/20 Healthcare Partners. The company is developing a device to aid in treating amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases by removing toxic proteins from cerebrospinal fluid (CSF).
Fisher Wallace Laboratories of New York has filed a citizen’s petition with the U.S. FDA regarding the agency’s proposed class III designation for cranial electrotherapy stimulators (CES) for treatment of depression. The company argued that the agency disallowed evidence at an advisory hearing regarding this therapy provided by direct rather than alternating current, but also that the FDA had reneged on an earlier decision to classify these devices as class II devices.
Keeping you up to date on recent developments in neurology, including: PTSD linked to a dysfunction of the brain networks that control memory; Molecule offers hope for halting Parkinson's; Brain abnormalities associated with schizophrenia in individuals with 22q revealed.
For depression, and other mental health disorders, the era of precision medicine has yet to arrive.
Symptoms are “very poorly reflective of the underlying biology,” Amit Etkin told BioWorld. Depression can manifest through multiple different symptoms that differ both between and within cultures.
Keeping you up to date on recent developments in neurology, including: Online therapy for lingering depression could fill gap in care; UTHealth develops technology to differentiate between PD and multiple system atrophy; Myelin is deregulated in autism spectrum disorder.
PARIS – Sensome SAS, of Palaiseau, France, has closed a second funding round, of $9 million, with its original French investors (Kurma Partners SA, Invest Partners SA, BNP Paribas Développement SA and the Paris-Saclay Seed Fund), now joined by the Japanese-based Asahi Intecc Co. Ltd.
Keeping you up to date on recent developments in neurology, including: Improving memory with noninvasive electrostimulation successfully studied in mice; AI analysis can predict progression of neurodegenerative disease from blood test; Study finds that after stroke, brain drowns in its own fluid; Immune response in brain, spinal cord could offer clues to treating neurological diseases.
Early detection of neurodegenerative disease even before symptoms emerge is the ideal when it comes to trying to treat or prevent progression. But that has remained difficult, as brain tissue that isn’t available until after death is typically the most definitive. Now, researchers have used an artificial intelligence (AI) algorithm to identify genetic expression data over time and correlate them in blood and postmortem brain tissue samples from subjects with either Alzheimer’s or Huntington’s disease.
RSS
